Cancer Treatment Research federal funding in FY2025

What the 93.395 × FY2025 join is

CFDA 93.395 and fiscal year 2025 meet here. $985,283,057.22 is the obligation sum on awards that carry both tags. A cancer-treatment-research award coded to another year is out. A FY2025 award under a different cancer CFDA is out even if the science sounds related. This packet does not name institutes, trial sites, or investigators. Unique recipients are unpublished.

Program-wide 3,545 awards totaling $8,755,707,172.30 remain the parent. Open CFDA 93.395, FY2025 federal spending, All programs, and All spending ties for the program book, the year hub, sibling codes, and other pairs. Do not add those pages into $985,283,057.22.

784 actions inside an $8.76 billion extract

Dividing $985,283,057.22 by 784 yields about $1,256,738.59. Research portfolios mix new awards, renewals, and supplements; 784 is not 784 unique labs. Means are not medians. Do not invent contractor or campus names.

FY2025’s share of $8,755,707,172.30 is a descriptive ratio of packet facts, not a finding that treatment research slowed. Correlation is not causation. Other years are not this page. Do not subtract the year cell from the program total and treat the remainder as a published table.

Not a trial registry or a survival score

$985,283,057.22 does not measure patients enrolled, drugs approved, or survival rates. Those series are unpublished here. The cell sums obligations with CFDA 93.395 and a FY2025 tag. Medical advice is outside this page. Catalog title text is the heading, not an efficacy claim. This page does not split the total by cancer type.

Obligations, not outlays

Even a thick research file records commitments, not necessarily payments. $985,283,057.22 can include multi-year project periods that pay later. Citing it as cash already spent on cancer treatment research over-reads the field. No outlay total is in this packet.

Keep both keys. Dropping the year turns the figure into the program book; dropping the CFDA turns it into a year hub that includes unrelated science.

Citing Cancer Treatment Research in FY2025

Cite USAspending.gov: Cancer Treatment Research (CFDA 93.395) obligated $985,283,057.22 on 784 awards in FY2025. Name both sides. Keep “obligations.” The compact $985 million is the same cell rounded. Prefer CFDA 93.395 if the program table refreshed.

FY2025 federal spending still includes every other CFDA tagged to that year. All programs lists sibling codes. All spending ties indexes other pairs. A later ingest can restate $985,283,057.22 without changing the join definition.

A minority slice of an $8.76 billion treatment-research book

Seven hundred eighty-four awards totaling $985,283,057.22 sit inside $8,755,707,172.30 on 3,545 awards program-wide. FY2025 is a minority slice by dollars, not a finding that treatment research slowed. The implied mean near $1,256,738.59 is a research-grant texture cue. 784 is not 784 clinical trials and not 784 unique labs. This packet does not name institutes, trial sites, or investigators. Patients enrolled, approvals, and survival rates are unpublished. Medical advice is outside this page. Cancer Biology Research is a different CFDA and a different join even when the campus is the same legal entity this packet does not name.

Cite CFDA 93.395 × FY2025, obligations not outlays. Multi-year project periods can obligate in one year and pay later. CFDA 93.395, FY2025 federal spending, All programs, and All spending ties stay the four hrefs. Do not stack them onto $985,283,057.22. Do not subtract the year cell from the program extract and treat the remainder as a published other-year table. Unique recipients remain unpublished. If the program table refreshes, prefer CFDA 93.395 and rewrite only the sentence whose source moved.

Treatment-research folklore does not add survival curves. $985,283,057.22 on 784 records is CFDA 93.395 in FY2025. Patients, approvals, and trial IDs stay unpublished. Biology research is CFDA 93.396, a different join. CFDA 93.395, FY2025 federal spending, All programs, and All spending ties remain hubs. Medical advice is outside this page.

Questions

How much did Cancer Treatment Research obligate in FY2025?

USAspending.gov records $985,283,057.22 across 784 awards for CFDA 93.395 in fiscal year 2025. That is an obligation join, not an outlay, and not a count of patients or trials. The program-wide extract is $8,755,707,172.30 on 3,545 awards. Keep both keys when quoting the year cell.

Is $985,283,057.22 the entire cancer-treatment program?

No. Program-wide facts are $8,755,707,172.30 and 3,545 awards. FY2025 is one yearlyTrend row: 784 awards totaling $985,283,057.22. Other years are not this page. Original filings remain on USAspending.gov. Keep both sides of the join when quoting the cell. USAspending.gov remains the source.

Does 784 awards mean 784 clinical trials?

No. 784 is the award-record count. Combined with $985,283,057.22, the average is about $1,256,738.59. Unique recipients are unpublished. Renewals add rows. This packet does not name trials or investigators. Keep both sides of the join when quoting the cell. USAspending.gov remains the source.

Where is the live table?

CFDA 93.395 is the program hub. FY2025 federal spending is the year hub. All programs lists other assistance codes. All spending ties lists other joins. Keep both sides when citing $985,283,057.22. Obligations are not outlays. Keep both sides of the join when quoting the cell. USAspending.gov remains the source.